These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 27993292

  • 1. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
    Buhl R, Magder S, Bothner U, Tetzlaff K, Voß F, Loaiza L, Vogelmeier CF, McGarvey L.
    Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
    Ichinose M, Taniguchi H, Takizawa A, Grönke L, Loaiza L, Voß F, Zhao Y, Fukuchi Y.
    Int J Chron Obstruct Pulmon Dis; 2016 Jan; 11():2017-27. PubMed ID: 27621608
    [Abstract] [Full Text] [Related]

  • 3. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A, Tetzlaff K, Derom E.
    Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
    [Abstract] [Full Text] [Related]

  • 4. Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies.
    LaForce C, Derom E, Bothner U, Kloer IM, Trampisch M, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2018 Jun; 13():1819-1831. PubMed ID: 29910611
    [Abstract] [Full Text] [Related]

  • 5. Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials.
    Ferguson GT, Buhl R, Bothner U, Hoz A, Voß F, Anzueto A, Calverley PMA.
    Respir Med; 2018 Oct; 143():67-73. PubMed ID: 30261995
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age.
    Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2016 Oct; 11():2701-2710. PubMed ID: 27843306
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
    ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R.
    Int J Chron Obstruct Pulmon Dis; 2014 Oct; 9():1133-44. PubMed ID: 25342898
    [Abstract] [Full Text] [Related]

  • 8. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.
    Calverley PMA, Anzueto AR, Carter K, Grönke L, Hallmann C, Jenkins C, Wedzicha J, Rabe KF.
    Lancet Respir Med; 2018 May; 6(5):337-344. PubMed ID: 29605624
    [Abstract] [Full Text] [Related]

  • 9. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting.
    Steinmetz KO, Abenhardt B, Pabst S, Hänsel M, Kondla A, Bayer V, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2019 May; 14():1441-1453. PubMed ID: 31308649
    [Abstract] [Full Text] [Related]

  • 10. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
    Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T.
    Int J Chron Obstruct Pulmon Dis; 2016 May; 11():891-8. PubMed ID: 27217742
    [Abstract] [Full Text] [Related]

  • 11. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials.
    Rabe KF, Chalmers JD, Miravitlles M, Kocks JWH, Tsiligianni I, de la Hoz A, Xue W, Singh D, Ferguson GT, Wedzicha J.
    Adv Ther; 2021 Jan; 38(1):579-593. PubMed ID: 33175291
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
    Ferguson GT, Fležar M, Korn S, Korducki L, Grönke L, Abrahams R, Buhl R.
    Adv Ther; 2015 Jun; 32(6):523-36. PubMed ID: 26112656
    [Abstract] [Full Text] [Related]

  • 13. Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease.
    Bai C, Ichinose M, Lee SH, Lee KH, Jöns O, Bothner U, Zhao Y, Buhl R.
    Int J Chron Obstruct Pulmon Dis; 2017 Jun; 12():3329-3339. PubMed ID: 29200840
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
    Derom E, Brusselle GG, Joos GF.
    Int J Chron Obstruct Pulmon Dis; 2016 Jun; 11():3163-3177. PubMed ID: 28008243
    [Abstract] [Full Text] [Related]

  • 15. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO® and OTEMTO® Studies.
    Buhl R, Singh D, de la Hoz A, Xue W, Ferguson GT.
    Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials.
    Buhl R, de la Hoz A, Xue W, Singh D, Ferguson GT.
    Adv Ther; 2020 Oct; 37(10):4175-4189. PubMed ID: 32671684
    [Abstract] [Full Text] [Related]

  • 17. Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease.
    Ramadan WH, Kabbara WK, El Khoury GM, Al Assir SA.
    Int J Chron Obstruct Pulmon Dis; 2015 Oct; 10():2347-56. PubMed ID: 26586940
    [Abstract] [Full Text] [Related]

  • 18. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
    Singh D, Gaga M, Schmidt O, Bjermer L, Grönke L, Voß F, Ferguson GT.
    Respir Res; 2016 Jun 18; 17(1):73. PubMed ID: 27316465
    [Abstract] [Full Text] [Related]

  • 19. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
    Singh D, Ferguson GT, Bolitschek J, Grönke L, Hallmann C, Bennett N, Abrahams R, Schmidt O, Bjermer L.
    Respir Med; 2015 Oct 18; 109(10):1312-9. PubMed ID: 26320402
    [Abstract] [Full Text] [Related]

  • 20. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
    Maltais F, O'Donnell D, Gáldiz Iturri JB, Kirsten AM, Singh D, Hamilton A, Tetzlaff K, Zhao Y, Casaburi R.
    Ther Adv Respir Dis; 2018 Oct 18; 12():1753465818755091. PubMed ID: 29439648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.